← back to search

Eva Schuth

Amgen (United States) · US
Area of research
Oncology · Radiology, Nuclear Medicine and Imaging
Research interest
Research interests include Medicine, Internal medicine, Hazard ratio, Gastroenterology, Adverse effect, and Ovarian cancer.
h-index
—
citations
127
works
2
NIH funding
—
primary concept
—
email
✉ Find email ↗

Recent publications

Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer
Gynecologic Oncology 2020cited by 30position: middledoi
Anti-NaPi2b antibody–drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study
Annals of Oncology 2018cited by 97position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

— · 2 papers (2018–2020)Eric W. Humke · Stanford University2 papers (2018–2020)Anjali Vaze · Amgen (United States)2 papers (2018–2020)Kathleen N. Moore · Oklahoma City University2 papers (2018–2020)Daniel Maslyar · Amgen (United States)2 papers (2018–2020)Michael J. Birrer · University of Arkansas at Little Rock2 papers (2018–2020)Erika Hamilton · Duke Medical Center2 papers (2018–2020)— · 2 papers (2018–2020)— · 1 papers (2018–2018)Divya Samineni · Roche (Switzerland)1 papers (2020–2020)J.F. Liu · Boston University1 papers (2018–2018)— · 1 papers (2018–2018)— · 1 papers (2020–2020)Alexandra Léary · Inserm1 papers (2018–2018)Peter C. Trask · National Institute of Standards and Technology1 papers (2018–2018)— · 1 papers (2018–2018)YounJeong Choi · Amgen (United States)1 papers (2020–2020)Joyce F. Liu · Harvard University1 papers (2020–2020)— · 1 papers (2018–2018)Susana Banerjee · Royal Marsden NHS Foundation Trust1 papers (2018–2018)